Wealthtrust Axiom Trimmed Its Exelon (EXC) Stake; Portola Pharmaceuticals (PTLA) Shorts Decreased By 2.24%

February 18, 2018 - By Richard Conner

Wealthtrust Axiom Llc decreased Exelon Corp (EXC) stake by 21.16% reported in 2017Q3 SEC filing. Wealthtrust Axiom Llc sold 17,854 shares as Exelon Corp (EXC)’s stock declined 1.46%. The Wealthtrust Axiom Llc holds 66,537 shares with $2.51M value, down from 84,391 last quarter. Exelon Corp now has $36.46B valuation. The stock increased 0.75% or $0.28 during the last trading session, reaching $37.78. About 9.45M shares traded or 49.61% up from the average. Exelon Corporation (NYSE:EXC) has risen 2.57% since February 18, 2017 and is uptrending. It has underperformed by 14.13% the S&P500.

Portola Pharmaceuticals Incorporated (NASDAQ:PTLA) had a decrease of 2.24% in short interest. PTLA’s SI was 3.68 million shares in February as released by FINRA. Its down 2.24% from 3.76 million shares previously. With 542,000 avg volume, 7 days are for Portola Pharmaceuticals Incorporated (NASDAQ:PTLA)’s short sellers to cover PTLA’s short positions. The SI to Portola Pharmaceuticals Incorporated’s float is 8.15%. The stock decreased 0.56% or $0.27 during the last trading session, reaching $47.69. About 400,018 shares traded. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has risen 51.17% since February 18, 2017 and is uptrending. It has outperformed by 34.47% the S&P500.

Investors sentiment decreased to 1.05 in Q3 2017. Its down 0.09, from 1.14 in 2017Q2. It dived, as 48 investors sold EXC shares while 239 reduced holdings. 63 funds opened positions while 237 raised stakes. 726.69 million shares or 0.50% more from 723.10 million shares in 2017Q2 were reported. Paradigm Asset Mngmt Company owns 98,100 shares for 0.96% of their portfolio. Middleton Company Ma invested in 0.55% or 80,880 shares. Rampart Mngmt owns 0.16% invested in Exelon Corporation (NYSE:EXC) for 12,677 shares. Arrowgrass Partners (Us) Limited Partnership owns 0% invested in Exelon Corporation (NYSE:EXC) for 1,087 shares. Dana Invest Advisors Inc owns 645,366 shares or 1.12% of their US portfolio. Ls Inv Advisors Limited Com invested 0.08% in Exelon Corporation (NYSE:EXC). Pictet Asset Mngmt Limited accumulated 5.17M shares. Mark Sheptoff Fincl Planning Limited Liability Corporation holds 0.01% in Exelon Corporation (NYSE:EXC) or 300 shares. 56.89M are held by State Street. Davenport And invested in 6,819 shares. Hsbc Hldgs Pcl reported 1.69 million shares or 0.1% of all its holdings. Srb has 0.02% invested in Exelon Corporation (NYSE:EXC). Kentucky Retirement Sys Insurance Tru Fund reported 0.16% of its portfolio in Exelon Corporation (NYSE:EXC). Tcw invested in 16,092 shares or 0% of the stock. Shufro Rose And Limited Liability Corporation has 0.03% invested in Exelon Corporation (NYSE:EXC).

Among 21 analysts covering Exelon Corporation (NYSE:EXC), 13 have Buy rating, 2 Sell and 6 Hold. Therefore 62% are positive. Exelon Corporation had 71 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of Exelon Corporation (NYSE:EXC) has “Buy” rating given on Wednesday, January 27 by Citigroup. As per Wednesday, December 13, the company rating was maintained by Morgan Stanley. Jefferies maintained Exelon Corporation (NYSE:EXC) on Thursday, August 3 with “Buy” rating. As per Tuesday, November 17, the company rating was initiated by Howard Weil. Guggenheim upgraded the shares of EXC in report on Friday, September 25 to “Buy” rating. The stock of Exelon Corporation (NYSE:EXC) has “Overweight” rating given on Friday, November 18 by Morgan Stanley. SunTrust maintained the shares of EXC in report on Wednesday, October 18 with “Buy” rating. The stock has “Peer Perform” rating by Wolfe Research on Thursday, March 24. The rating was maintained by RBC Capital Markets on Sunday, November 5 with “Buy”. The rating was maintained by Wells Fargo with “Buy” on Monday, August 31.

Since September 11, 2017, it had 0 insider buys, and 3 sales for $24.20 million activity. The insider SHATTUCK MAYO A III sold 567,070 shares worth $22.75 million. Aliabadi Paymon also sold $510,787 worth of Exelon Corporation (NYSE:EXC) shares. Cornew Kenneth W. also sold $936,000 worth of Exelon Corporation (NYSE:EXC) on Monday, September 25.

Investors sentiment increased to 2.16 in Q3 2017. Its up 0.85, from 1.31 in 2017Q2. It increased, as 20 investors sold Portola Pharmaceuticals, Inc. shares while 37 reduced holdings. 38 funds opened positions while 85 raised stakes. 56.33 million shares or 15.80% more from 48.64 million shares in 2017Q2 were reported. Geode Mgmt Ltd Limited Liability Company, a Massachusetts-based fund reported 576,301 shares. Emerald Advisers Inc Pa owns 1% invested in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) for 453,921 shares. Zevenbergen Invs Ltd Company reported 1.35% of its portfolio in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Citadel Ltd has 0.04% invested in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Millennium Mngmt Lc has invested 0.04% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Polar Capital Llp holds 588,200 shares or 0.36% of its portfolio. Loring Wolcott Coolidge Fiduciary Advsrs Limited Liability Partnership Ma owns 10 shares. Dimensional Fund Advisors L P holds 12,247 shares or 0% of its portfolio. Amer Int stated it has 36,631 shares. Stifel Financial Corp has 4,964 shares. Castleark Mgmt Limited invested 0.17% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Wells Fargo And Mn holds 46,793 shares. Tudor Invest Et Al accumulated 0.04% or 31,961 shares. Fernwood Mgmt Llc has invested 7.77% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Evanson Asset Management Lc holds 5,000 shares.

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation. The company has market cap of $3.11 billion. The firm is developing Betrixaban, an oral once-daily inhibitor of Factor Xa that is in Phase III clinical stage for extended duration VTE prophylaxis in acute medically ill patients for 35 days of in-hospital and post-discharge use; Andexanet alfa, a recombinant protein, which is in Phase III and IV stages for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, an orally available dual kinase inhibitor, which is in Phase IIa clinical stage for hematologic, blood, cancers, and inflammatory disorders. It currently has negative earnings. It also develops Syk-selective inhibitors in pre-clinical stage for allergic conjunctivitis.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: